All In Biotech

Drug Trial Radar · NCT07465276

Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC

Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable Squamous Cell Carcinoma of the Head and Neck: a Phase 2 Trial

Last checked: Nov 19, 2026Latest source record: Mar 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

32

Planned (sponsor's estimate)

Start

Mar 26, 2026

Primary completion

Apr 30, 2028

Study completion Apr 30, 2030

Sponsor

Lead sponsor
Dana-Farber Cancer InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Bicara Therapeutics
First posted
Mar 11, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is to evaluate the safety and efficacy of ficerafusp alfa in combination with pembrolizumab prior to surgical resection in participants with resectable, high-risk, locoregionally advanced, PD-L1-positive squamous cell carcinoma of the head and neck (HNSCC). The names of the study drugs used in this research study are: * ficerafusp alfa (a type of bifunctional antibody and recombinant fusion protein) * pembrolizumab (a type of monoclonal antibody)

Conditions

  • Head and Neck Squamous Cell Carcinoma (HNSCC)
  • Squamous Cell Carcinoma of the Head and Neck

Interventions

  • Ficerafusp alfaDrug

    Bifunctional antibody and recombinant fusion protein, single-use vial, via intravenous (into the vein) infusion per protocol.

  • PembrolizumabDrug

    Monoclonal antibody, single-dose vial, via intravenous infusion per protocol.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pathologic Treatment Response-2 (pTR-2) RateTime frame: Assessed at time of surgical resection, between days 30 and 42 from start of neoadjuvant treatment.

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Brigham and Women's Hospital

    Boston, Massachusetts · Recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.